We are live on ! Find out more
RUBY

Rubius Therapeutics, Inc

Delisted

RUBY was delisted on the 6th of March, 2023.

55 hedge funds and large institutions have $1.54B invested in Rubius Therapeutics, Inc in 2018 Q3 according to their latest regulatory filings, with 55 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
+55
Holders Change %
% of All Funds
1.26%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
55
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$11K +$10.1K +441 New
SPIA
52
Steward Partners Investment Advisory
New York
$8K +$8K +350 New
CCA
53
Catalyst Capital Advisors
New York
$6K +$5.72K +250 New
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$2K +$1.92K +84 New
BNP Paribas Financial Markets
55
BNP Paribas Financial Markets
France
$1.25K +$1.19K +52 New

RUBY Hedge Fund Activity: Q3 2018 in Review

55 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q3 2018, worth a combined $1.54B.

Buyers outnumbered sellers: 55 funds opened new RUBY positions and 0 closed out — a net gain of 55 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Flagship Pioneering, opening a new position worth an estimated $876M.

  • 55 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $1.54B of Rubius Therapeutics, Inc stock for Q3 2018.
  • 55 funds opened new Rubius Therapeutics, Inc positions in Q3 2018 and 0 closed out, a net change of +55 holders.
  • The largest Rubius Therapeutics, Inc buyer in Q3 2018 was Flagship Pioneering, an estimated $876M added.

Based on aggregated 13F filings for Q3 2018.